Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Journal of Nuclear Medicine
Journal
Overview
Identity
Overview
Publication Venue For
Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets
. 62:131-136.
2021
Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies
. 60:736-744.
2019
Production of
15
O for medical applications via the
16
O(g,n)
15
O reaction
. 60:424-428.
2019
Production and Use of the First-Row Transition Metal PET Radionuclides
43,44
Sc,
52
Mn, and
45
Ti
. 59:1655-1659.
2018
Imaging melphalan therapy response in preclinical extramedullary multiple myeloma with
18
F-FDOPA and
18
F-FDG PET
. 59:1551-1557.
2018
ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body.
. 58:1174-1176.
2017
Noninvasive imaging of colitis using multispectral optoacoustic tomography
. 58:1009-1012.
2017
Repeatability of
18
F-FLT PET in a multicenter study of patients with high-grade glioma
. 58:393-398.
2017
Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients
. 58:246-251.
2017
A systematic approach for developing bacteria-specific imaging tracers
. 58:144-150.
2017
PET/MRI of hypoxic atherosclerosis using
64
Cu-ATSM in a rabbit model
. 57:2006-2011.
2016
18
F-Fluciclovine (FACBC) and its potential use for breast cancer imaging
. 57:1329-1330.
2016
Working Together to Advance Women in Nuclear Medicine.
. 57:14N.
2016
SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0.
. 57:1316-1322.
2016
Impact of MR-Based Attenuation Correction on Neurologic PET Studies.
. 57:913-917.
2016
Microfluidic preparation of a
89
Zr-Labeled trastuzumab single-patient dose
. 57:747-752.
2016
2015 SNMMI highlights lecture: General nuclear medicine
. 57:13N-18N.
2016
Pretargeted immuno-PET: Overcoming limitations of space and time
. 57:332-333.
2016
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.
. 57:151-162.
2016
Successful translation of fluorescence navigation during oncologic surgery: A consensus report
. 57:144-150.
2016
18
F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer
. 56:1003-1010.
2015
American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain.
. 56:642-645.
2015
MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations
. 55:1557-1564.
2014
Development of a radiolabeled irreversible peptide ligand for PET imaging of vascular endothelial growth factor
. 55:1029-1034.
2014
Glypican-3-targeted
89
Zr PET imaging of hepatocellular carcinoma: Where antibody imaging dares to tread
. 55:708-709.
2014
A standardized light-emitting diode device for photoimmunotherapy
. 55:1893-1898.
2014
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with
212
Pb-TCMC-trastuzumab
. 55:1636-1642.
2014
MIRD pamphlet No. 24: Guidelines for quantitative
131
I SPECT in dosimetry applications
. 54:2182-2188.
2013
Designing the magic bullet? the advancement of immuno-PET into clinical use
. 54:1171-1174.
2013
18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.
. 54:1120-1126.
2013
PET with
18
F-FDG-Labeled T lymphocytes for diagnosis of acute rat renal allograft rejection
. 54:1147-1153.
2013
Radiolabeled amino acids for oncologic imaging.
. 54:1007-1010.
2013
A cross-sectional analysis of nuclear medicine technologists in the US concerning radiological emergency preparedness
. 54.
2013
ABNM position statement: Nuclear medicine professional competency and scope of practice
. 52:994-997.
2011
Components of a curriculum for molecular imaging scientists
. 52:650-656.
2011
Potential of noninvasive serial assessment of acute renal allograft rejection by
18
F-FDG PET to monitor treatment efficiency
. 51:1644-1652.
2010
MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy
. 51:311-328.
2010
Impact of rituximab treatment on
90
Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma
. 51:150-157.
2010
Assessment of an
18
F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer
. 50:2042-2048.
2009
MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for
111
In-And
90
Y-ibritumomab Tiuxetan
. 50:644-652.
2009
MIRD commentary: Proposed name for a dosimetry unit applicable to deterministic biological effects-the barendsen (Bd)
. 50:485-487.
2009
MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature
. 50:477-484.
2009
MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy
. 49:1884-1899.
2008
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae
. 49:279-284.
2008
Diagnostic performance of an expert system for interpretation of
99m
Tc MAG3 scans in suspected renal obstruction
. 49:216-224.
2008
Procedure guideline for SPECT/CT imaging 1.0
. 47:1227-1234.
2006
Procedure guideline for tumor imaging with
18
F-FDG PET/CT 1.0
. 47:885-895.
2006
166
Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy
. 47:534-542.
2006
RENEX: An expert system for the interpretation of
99m
Tc-MAG3 scans to detect renal obstruction
. 47:320-329.
2006
Imaging glioma extent with
131
I-TM-601
. 46:580-586.
2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies
. 46:642-651.
2005
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry
. 46:1034-1041.
2005
Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance
. 46:1225-1239.
2005
Radiotargeted gene therapy
. 46.
2005
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison
. 45:1725-1733.
2004
Invited commentary: targeting of 125I-labeled B lymphocyte stimulator.
. 44:434-436.
2003
Targeting of
125
I-labeled B lymphocyte stimulator
. 44:434-436.
2003
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting
90
Y-antibody therapy
. 43:1245-1253.
2002
A bayesian regression model for plasma clearance
. 43:762-766.
2002
Metabolite production in patients with lymphoma after radiometal-labeled antibody administration
. 42:1324-1333.
2001
Prediction of renal transplant survival from early postoperative radioisotope studies
. 41:1332-1336.
2000
Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with
99m
Tc or
188
Re
. 41:887-895.
2000
Radiation dosimetry for
90
Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using
111
In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
. 41:952-958.
2000
A clinical trial of radioimmunotherapy with
67
Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma
. 40:2014-2020.
1999
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body
. 40:2102-2106.
1999
Mouse models for internal radiation dosimetry [4] (multiple letters)
. 40:1969-1970.
1999
Factors affecting
131
I-Lym-1 pharmacokinetics and radiationdosimetry in patients with non-Hodgkin's lymphoma and chroniclymphocytic leukemia
. 40:1317-1326.
1999
Reproducibility of single-sample clearance of
99m
Tc- mercaptoacetyltriglycine and
131
I-orthoiodohippurate
. 40:1122-1124.
1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
. 40:302-310.
1999
67
Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma
. 40:302-310.
1999
Procedure guideline for diagnosis of renovascular hypertension
. 39:1297-1302.
1998
A mouse bone marrow dosimetry model
. 39:1243-1247.
1998
A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy
. 39:1223-1229.
1998
Prediction of urinary excretion of technetium-99m-MAG3
. 39:1257-1259.
1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts
. 39:842-849.
1998
Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH
2
in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer
. 38:1221-1229.
1997
Radioimmunotherapy for breast cancer using indium-11 l/yttrium-90 BrE-3: Results of a phase i clinical trial
. 38:1180-1185.
1997
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources
. 38:1374-1378.
1997
Exercise-rest same-day SPECT sestamibi imaging to detect coronary artery disease
. 38:200-203.
1997
Fluorine-18-FPCT: A PET radiotracer for imaging dopamine transporters
. 38:119-126.
1997
Gallium-67 Imaging of Pericardial Lymphoma in AIDS
. 37:995-996.
1996
Myocardial Viability: Unresolved Issues
. 37:794-797.
1996
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies
. 37:1970-1975.
1996
Procedure guideline for general imaging: 1.0
. 37:2087-2092.
1996
Procedure guideline for general imaging: 1.0. Society of Nuclear Medicine.
. 37:2087-2092.
1996
Consensus report on ACE inhibitor renography for detecting renovascular hypertension
. 37:1876-1882.
1996
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49
. 37:1491-1496.
1996
Measurement of Renal Function with Technetium-99m-MAG3 in Children and Adults
. 37:588-593.
1996
Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator
. 37:302-306.
1996
Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy
. 37:146-150.
1996
Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer
. 36:2229-2233.
1995
Prediction of improvement in left ventricular function with iodine-123-IPPA after coronary revascularization.
. 36:1987-1993.
1995
Comparison of single-injection multisample renal clearance methods with and without urine collection
. 36:603-606.
1995
Quantitative SPECT imaging: A review and recommendations by the focus committee of the society of nuclear medicine Computer and Instrumentation Council
. 36:1489-1513.
1995
Renal clearance of technetium-99m-MAG3: Normal values [3]
. 36:706-708.
1995
Adenosine myocardial perfusion imaging
. 35:734-736.
1994
Biokinetics of thallium-201 in normal subjects: Comparison between adenosine, dipyridamole, dobutamine and exercise
. 35:535-541.
1994
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung
. 35:1381-1389.
1994
Quantitation of renal parenchymal retention of technetium-99m-MAG3 in renal transplants
. 35:846-850.
1994
Sequential dual-isotope SPECT imaging with thallium-201 and technetium- 99m-sestamibi
. 35:549-553.
1994
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
. 35:1017-1022.
1994
When is myocardial viability an important clinical issue?
. 35.
1994
Indium-111-labeled polyclonal human immunoglobulin: Identifying focal infection in patients positive for human immunodeficiency virus
. 34:1621-1625.
1993
Thallium reinjection imaging: The search for an optimal protocol
. 34:743-746.
1993
Comparison of same-day protocols using technetium-99m-sestamibi myocardial imaging
. 33:186-191.
1992
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer
. 33:1648-1653.
1992
Early thallium imaging after percutaneous transluminal coronary angioplasty: Tomographic evaluation during adenosine-induced coronary hyperemia
. 33:2086-2089.
1992
Mean time parameters reveal differences in the pharmacokinetics of indium- 111 and iodine-131-labeled B72.3 monoclonal antibody
. 33:2248-2250.
1992
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer
. 33:23-29.
1992
Renal transplant hypertension caused by iliac artery stenosis
. 33:1178-1180.
1992
Editorial: Is redistribution important in sestamibi myocardial imaging?
. 32:1966-1967.
1991
Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody
. 32:1162-1168.
1991
Quantitation of renal function using MAG
3
. 32:2061-2063.
1991
Simplified methods for renal clearance in children: Scaling for patient size
. 32:1821-1825.
1991
Measurement of renal function with radionuclides
. 30:2053-2057.
1989
Quantitation of renal function with technetium-99m MAG
3
. 29:1931-1933.
1988
Abnormal captopril renogram with a technetium-99m-labeled hippuran analog
. 29:1730-1737.
1988
Comparison of technetium-99m MAG
3
with iodine-131 hippuran by a simultaneous dual channel technique
. 29:1189-1193.
1988
Estimation of extracellular fluid volume from plasma clearance on Technetium-99m DTPA by a single-injection, two-sample method
. 29:255-258.
1988
Uncontrolled variables in the measurement of renal function.
. 27:1644.
1986
Gates method for GFR measurement.
. 27:1373-1374.
1986
Measurement of glomerular filtration rate: Single injection plasma clearance method without urine collection
. 26:1243-1247.
1985
Gallium-67 scanning in Sjogren's syndrome: Concise communication
. 25:299-302.
1984
Quality control of Tc-99m DTPA for measurement of glomerular filtration: concise communication
. 24:722-727.
1983
Localization of radiolabeled mouse alloantibody in a sarcoma induced by 3-methylcholanthrene
. 21:77-80.
1980
Use of blood-pool imaging in evaluation of diffuse activity patterns in technetium-99m pyrophosphate myocardial scintigraphy
. 20:496-501.
1979
Comprehensive evaluation of renal function in the transplanted kidney
. 16:1115-1120.
1975
Demonstration of a chemodectoma by perfusion scanning: case report
. 16:472-473.
1975
Use of 99mTc as a radioisotopic label to study the migratory patterns of normal and neoplastic cells
. 15:656-661.
1974
Labeling of mammalian nucleated cells with (99m)Tc
. 14:706-708.
1973
Pancreatic visualization with 75 Se-selenomethionine after surgery.
. 13:765-766.
1972
Identity
International Standard Serial Number (issn)
0161-5505
Electronic International Standard Serial Number (eissn)
1535-5667
2159-662X